Male pattern baldness (also known as androgenic alopecia) is the most common type of hair loss in men. Affecting ∼50% of men above 40 years of age ([@bib22]), it is caused by interplay of genetic predisposition, hormones, and lifestyle factors including smoking, alcohol drinking and stress ([@bib22]; [@bib6]). From a hormonal perspective, the primary contributor is dihydrotestosterone (DHT) ([@bib22]). When circulating testosterone enters hair follicles, particularly balding hair follicles, the enzyme 5*α*-reductase metabolises testosterone to biologically more potent DHT that strongly binds to the androgen receptor and alters gene expression, leading hair follicles to shorten their growth phase and to miniaturise ([@bib22]). Finasteride, a commonly prescribed drug for male pattern baldness, acts by inhibiting the conversion of testosterone to DHT ([@bib1]). Yet, not only androgens but also insulin-like growth factor 1 (IGF-1) and insulin may be implicated in male pattern baldness, as indicated by men with baldness having elevated levels of circulating IGF-1 ([@bib26]; [@bib21]) or an increased risk of hyperinsulinaemia/insulin resistance ([@bib28]).

Testosterone, IGF-1, and insulin are also implicated in the pathogenesis of colorectal neoplasia (cancer (CRC) and its precursory adenoma (CRA)). Although evidence is still limited, androgens may protect against colorectal neoplasia in men through its direct activation of the androgen signalling pathway, leading to reduced expression of oncogenes modulated by *β*-catenin or by exerting favourable effects on major risk factors for colorectal neoplasia such as obesity and insulin resistance ([@bib16]). In line with this hypothesis, previous studies reported an inverse association between circulating testosterone and the risk of colorectal cancer in men ([@bib11]; [@bib17]). Bioavailable IGF-1 increases proliferation and decreases apoptosis of colonocytes, thereby promoting colorectal carcinogenesis ([@bib7]; [@bib25]). Insulin, apart from its direct mitogenic effect on neoplastic cells, also acts by enhancing bioavailability of IGF-1 through suppressing hepatic production of hormonal binding proteins including IGFBP-1 ([@bib9]). Insulin-like growth factor 1 exerts more potent growth-promoting and antiapoptotic effects than insulin ([@bib9]). Therefore, it is biologically plausible that male pattern baldness, as a marker of underlying aberration in the regulation of androgens, IGF-1, and/or insulin, may be associated with colorectal neoplasia. Yet, no epidemiologic study has evaluated the relationship. Thus, we prospectively examined male pattern baldness at age 45 years in relation to risks of CRC and CRA in the Health Professionals Follow-Up Study (HPFS).

Materials and methods
=====================

Study population
----------------

The HPFS began in 1986, enrolling 51 529 male health professionals in the United States between 40 and 75 years of age. Participants completed a questionnaire on demographics, medical history, and lifestyle factors at enrolment and have updated information through biennial follow-up questionnaires. They also reported dietary intake through a validated semiquantitative food questionnaire ([@bib24]; [@bib5]) at enrolment and every 4 years thereafter. Follow-up rates have exceeded 90% in each 2-year cycle.

For this analysis, the baseline year was defined as 1992 when information on hair pattern at age 45 years was collected. At baseline, the mean age of participants was 60.5 years (s.d. of 9.8 years). We excluded men with a prior diagnosis of CRC or polyp (adenoma analysis only), those who left the hair pattern question blank, and those who developed ulcerative colitis before baseline or over the follow-up. Of note, because of the asymptomatic nature of adenomas, adenomas are generally detected during endoscopic procedures for screening or unrelated gastrointestinal conditions. To minimise potential for detection bias induced by differential frequency of endoscopy across hair patterns, we restricted adenoma analysis to those who underwent at least one colonoscopy or sigmoidoscopy between 1992 and 2010. After these exclusions, 32 782 men for CRC analysis and 29 770 men for adenoma analysis remained eligible for the follow-up from 1992 through 2010.

Assessment of exposure
----------------------

The 1992 questionnaire asked participants to select their hair pattern at age 45 years from the five images (no baldness, frontal-only baldness, frontal-plus-mild-vertex baldness, frontal-plus-moderate-vertex baldness, and frontal-plus-severe-vertex baldness) modified from the Hamilton--Norwood scale ([Figure 1](#fig1){ref-type="fig"}; [@bib18]). Of the five hair categories, the four baldness patterns were collectively termed as any baldness in this study.

Assessment of covariates
------------------------

Information on potential confounders and intermediates, determined *a priori* from known or suspected risk factors for colorectal neoplasia, was collected at baseline and throughout follow-up. The following lists the definitions of the covariates used for this study: age (years in continuous for cancer analyses; \<64.9, 65--69.9, 70--74.9, 75--79.9, ⩾80 years for adenoma analyses), race (White *vs* nonwhite), body mass index (kg m^−2^ in quintiles), physical activity (metabolic equivalent task (MET)-hours per week in quintiles), personal history of diabetes mellitus (yes *vs* no), personal history of endoscopy and polyp detection (no endoscopy+no polyp detection, endoscopy+no polyp detection, endoscopy+polyp detection), time period of endoscopy (integer indicating questionnaire cycles in continuous), number of endoscopies received (continuous), time since the most recent endoscopy (years in continuous), reason for the current endoscopy (screening *vs* symptoms), family history of colon cancer (yes *vs* no), smoking habits (never smoker, 0.1--4.9, 5--19.9, 20--39.9, 40+ pack-years), aspirin use (yes *vs* no), multivitamin use (yes *vs* no), finasteride use (yes *vs* no), total calorie intake (kcal day^−1^ in quintiles), alcohol intake (0, 0.1--4.9, 5.0--14.9, ⩾15 g day^−1^), red and processed meat intake (quintiles in servings per day), folate intake (*μ*g day^−1^ in quintiles), calcium intake (mg day^−1^ in quintiles), and vitamin D intake (IU day^−1^ in quintiles).

Of note, micronutrient intakes included both dietary and supplemental sources. Covariates with missing values were handled via carry-forward or missing category (i.e., smoking habits, reason for the current endoscopy), but the proportion of participants with missing data was low for most covariates.

Ascertainment of outcome
------------------------

The case was defined as primary CRC restricted to invasive adenocarcinoma for cancer analysis; as adenomatous polyps for adenoma analysis. On biennial follow-up questionnaires through 2010, participants reported whether they were diagnosed with CRC or polyps. When a diagnosis was reported, after obtaining consent, study investigators blinded to the participants\' exposure status reviewed medical records to confirm the diagnosis and to extract information on tumour characteristics including anatomic location, histologic type, and size and number of polyps. Only confirmed cases were included in this analysis.

Statistical analysis
--------------------

For cancer analysis, hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between hair pattern at age 45 years and CRC risk were estimated based on Cox proportional hazards models using age as the underlying timescale. Following the Anderson--Gill data structure ([@bib27]), a new record was created in each questionnaire cycle for participants at risk by assigning covariates the value of the cycle before the current cycle. Person-time of follow-up was accrued from the date of return of the baseline questionnaire until the date of CRC diagnosis, date of death from any cause, or date of end of study (31 January 2010 for HPFS), whichever came first. The proportional hazard assumption regarding the exposure variable was verified by likelihood ratio test comparing the final multivariable model with and without four cross-product terms between categorical exposure and binary age (\<65, ⩾65 years).

For adenoma analysis, the Anderson--Gill data structure was used ([@bib27]), where a new data record was created each time men reported endoscopy at biennial follow-up questionnaires by assigning covariates the value of the cycle before the most recent endoscopy. When participants had multiple endoscopies during the follow-up, they contributed multiple data points until the endoscopy when the first adenoma was detected or the last endoscopy done (i.e., person-endoscopy at risk). To account for the correlation over repeated endoscopies for the same individual, logistic regressions for clustered data (SAS PROC GENMOD) was used to estimate odds ratios (ORs) and 95% CIs.

In multivariable analyses for colorectal neoplasia, potential confounders were adjusted for by updating their values whenever new information was obtained from the follow-up questionnaires. Time-invariant variables (race, family history of colon cancer) and variables with evidence of a long induction period to affect colorectal neoplasia (calcium ([@bib12], [@bib14]), folate ([@bib15]; [@bib13]), and aspirin ([@bib8]; [@bib2])) were adjusted for using baseline values. Of note, as finasteride use may lie along the causal pathway between male hair patterns and colorectal neoplasia, multivariable analyses were run without and with adjustment for finasteride use.

Colorectal neoplasia is a biologically heterogeneous disease that develops through distinctive aetiologic pathways ([@bib10]). To explore potential aetiologic heterogeneity in the relationships between hair pattern at age 45 years and colorectal neoplasia, we conducted subgroup analyses by subtypes of colorectal neoplasia defined by tumour characteristics including anatomic location (distal colon, proximal colon, rectum). We classified adenomas by histology ((tubulo)villous *vs* tubular); by size (large: ⩾1 cm *vs* small: \<1 cm in diameter); by multiplicity (⩾3 *vs* 1--2); by risk of progressing to CRC as indicated by the combined characteristics of histology, size, and multiplicity (high-risk: (tubulo)villous or high-grade dysplasia, large, or ⩾3 adenomas) *vs* low-risk: tubular, small, and 1--2 adenomas). Furthermore, in light of considerable distinction in the profile of genetic mutations between tubular and villous adenomas ([@bib29]; [@bib30]), we also examined heterogeneity by subdividing adenomas of large or ⩾3 by histologic origin (large or ⩾3 adenomas with (tubulo)villous origin *vs* large or ⩾3 adenomas with tubular origin).

Of note, sigmoidoscopy cannot detect proximal colon adenoma, potentially leading to outcome misclassification. Thus, for adenoma analysis, a sensitivity analysis was conducted by restricting the analytic cohort to men who had at least one colonoscopy. For participants with more than one adenoma diagnosed, analyses were performed using the adenoma of the largest size and most advanced histologic characteristics.

All the statistical tests were two sided and *P*-values of ⩽0.05 were considered statistically significant. Analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA).

Results
=======

We documented 710 incident cases of CRC among 32 782 eligible men over the mean follow-up of 15.6 years (510 507 person-years); 3526 cases of newly diagnosed CRA among 29 770 men who underwent at least one endoscopy between 1992 and 2010 (57 157 person-endoscopies). Across the analytic cohorts ([Table 1](#tbl1){ref-type="table"}), men with frontal-plus-severe-vertex baldness at age 45 years were more likely to have diabetes mellitus and to use aspirin and finasteride than men without baldness at age 45 years. In addition, within the analytic cohort for adenoma analysis, men with frontal-plus-severe-vertex baldness tended to engage in less physical activity and to have smoked more cigarettes. These differences tended to be slight, and other potential risk factors for colorectal neoplasia were distributed similarly across the different hair patterns. When the two analytic cohorts were compared, men in the adenoma analysis were less likely to be diabetic and more likely to be physically active; to have a family history of colon cancer; and to use multivitamin.

In the cancer analyses in relation to hair pattern at age 45 years ([Table 2](#tbl2){ref-type="table"}), evidence for an increased risk associated with any baldness compared with no baldness was suggestive for overall CRC (HR, 1.13; 95% CI, 0.97--1.32), but significant for colon cancer (HR, 1.24; 95% CI, 1.02--1.50), particularly proximal colon cancer (HR, 1.30; 95% CI, 1.00--1.68). Analyses by subtypes of baldness showed that the positive association was largely driven by frontal-only baldness and frontal-plus-mild-vertex baldness. Compared with men with no baldness, the risk of colon cancer increased by 29% for men with frontal-only baldness (HR, 1.29; 95% CI, 1.03--1.62) and by 31% for men with frontal-plus-mild-vertex baldness (HR, 1.31; 95% CI, 1.01--1.70). For proximal colon cancer, the HR comparing frontal-plus-mild-vertex baldness and no baldness amounted to 1.42 (95% CI, 1.00--2.02). Further adjustment for finasteride use barely changed the results (data not shown).

In the adenoma analyses in relation to hair pattern at age 45 years ([Table 3](#tbl3){ref-type="table"}), evidence for a positive association was diluted when analysed with composite exposure of any baldness, but became evident with some subtypes of baldness. Compared with no baldness, a statistically significant increased risk of CRA was observed for frontal-only baldness (OR, 1.16, 95% CI, 1.06 --1.26) and a borderline-insignificant positive association was observed for frontal-plus-severe-vertex baldness (OR, 1.14, 95% CI, 0.98--1.33). By anatomic subsites, the association with frontal-only baldness appeared stronger for distal colon and rectal adenomas, whereas that with frontal-plus-severe-vertex baldness was pronounced in the proximal colon and rectum adenomas. Upon restricting the analysis to men who had at least one colonoscopy, the results did not change materially except that the aforementioned associations became slightly stronger (data not shown); an association of rectal adenoma with frontal-only baldness became significant (OR, 1.30, 95% CI, 1.03--1.63, *P=*0.03).

The relationship between subtypes of hair pattern at age 45 years and adenoma was also heterogeneous by characteristics related to histopathology, size, and multiplicity ([Table 4](#tbl4){ref-type="table"}). An elevated risk associated with frontal-only baldness and frontal-plus-severe-vertex baldness was primarily with tubular adenoma, small adenoma, 1--2 adenomas, and low-risk adenoma. When adenomas of large size or with multiplicity (⩾3) were further stratified by histopathology, significant evidence of an increased risk associated with frontal-only baldness was observed for adenomas with tubular histopathology but not for adenomas with (tubulo)villous histopathology.

Discussion
==========

Among men, some patterns of baldness at age 45 years were significantly associated with an increased risk of colorectal neoplasia compared with no baldness. For cancer, frontal-only baldness and frontal-plus-mild-vertex baldness were positively associated with colon cancer but not with rectal cancer. For adenomas, an elevated risk of colon adenoma was also observed for frontal-only baldness but not with frontal-plus-mild-vertex baldness. In addition for rectal adenoma, suggestive nonsignificant positive associations were observed with frontal-only baldness and with frontal-plus-severe-vertex baldness. By subtypes of adenomas, these associations were largely confined to adenomas with tubular histopathology. Although a significant association was not observed for large or multiple adenomas overall, frontal-only baldness formed a significant positive association with large or multiple adenomas of tubular histology. Finasteride use had little influence on the results.

Previous studies on male pattern baldness and malignancy focused on prostate cancer because of its androgen dependency. In a recent prospective cohort study conducted among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, it was only frontal-plus-moderate-vertex baldness at age 45 years that was associated with an increased risk of aggressive prostate cancer ([@bib31]). This result juxtaposes our finding that it was only frontal-plus-moderate-vertex baldness at age 45 years that was not associated with any colorectal neoplasia. While the main hypothesis proposed to explain a positive association between baldness and prostate cancer relates to excess androgenicity ([@bib4]), for CRC development in men, high testosterone does not increase risk and may even be protective ([@bib16]). Thus, the type of baldness linked to an elevated risk of aggressive prostate cancer is not expected to be associated with an increased risk of colorectal neoplasia. Furthermore, evidence supporting elevated levels of circulating testosterone among bald men remains inconclusive ([@bib22]). Some studies observed normal levels of circulating testosterone among bald men ([@bib19]; [@bib20]), suggesting that responsiveness to circulating testosterone of hair follicles as determined by intracellular androgen receptor number and 5*α*-reductase activity may be more relevant to inducing male pattern baldness than circulating testosterone concentration *per se*.

Rather than testosterone, we hypothesise that the IGF-1 and insulin pathways may be factors linking male pattern baldness to colorectal neoplasia (particularly CRC). In a cross-sectional study that examined mutually adjusted levels of circulating testosterone, IGF-1, and other sex hormones and their binding proteins, only IGF-1 was significantly associated with an increased risk of baldness ([@bib26]). Moreover, a recent meta-analysis found that baldness was associated with an increased risk of insulin resistance (pooled OR, 4.88; 95% CI, 2.05--11.64) and hyperinsulinaemia (pooled OR, 1.97; 95% CI, 1.20--3.21) ([@bib28]). In our study, an increased risk associated with baldness was virtually confined to adenomas of small size, tubular histology, and/or 1--2 adenomas. Interestingly, in a recent study that examined insulin-related serum markers in relation to types of CRA in Caucasian males, circulating C-peptide, a marker of insulin secretion, was strongly associated with tubular adenomas (OR comparing extreme tertiles, 3.8; 95% CI, 1.3--11.2) ([@bib3]). Thus, the insulin pathway may be particularly relevant to linking baldness to tubular adenomas and, indeed in our study, a positive association was suggested for large or multiple adenomas if they are of tubular histology.

It is worth noting that an increased risk associated with frontal-plus-severe-vertex baldness was evident for CRA but not for CRC. The role of chance cannot be excluded. Yet, as for the association with frontal-only baldness, the association with frontal-plus-severe-vertex baldness was confined to adenomas of tubular histology. Although lack of studies on hormone profiles across each type of baldness hampers our understanding of biological mechanism underlying the heterogeneous finding, in light of an estimated 79% heritability of male pattern baldness ([@bib23]), reaching the most progressed type of baldness at age 45 years may be driven by a strong genetic influence. Thus, it is plausible that there are genetic polymorphisms common to severe baldness and adenomas of tubular histology.

Our finding that male pattern baldness was associated with risk of tubular but not (tubulo)villous adenoma may suggest some aetiologic insights. Tubulo-villous and villous adenomas are more likely to progress and be of advanced stage than tubular adenomas, and this may explain why baldness was weakly associated with overall high-risk adenomas. However, baldness was strongly and significantly associated with the subset of high-risk adenomas that had exclusively a tubular component.

There are several strengths in our study. To our knowledge, our study represents the first to report a potential relationship between male pattern baldness and the risk of colorectal neoplasia. By examining both adenoma and cancer outcomes and observing a positive association across neoplasias in colorectal carcinogenesis, we reduced the likelihood of chance findings. Furthermore, we had little evidence of confounding, as indicated by minimal association between baldness and lifestyle factors and little change in results from the age-adjusted to multivariable-adjusted model. By analysing by subtypes of colorectal neoplasia and accounting for finasteride use, our study was able to elucidate some mechanistic insight regarding the role of hormones across colorectal carcinogenesis.

Yet, our study has limitations. First, male pattern baldness at age 45 years was recalled and self-reported. Aside from random errors associated with recall, as baldness is considered unattractive, participants may have downgraded the severity of baldness. However, as this information was assessed before the diagnosis of colorectal neoplasia, misclassification is likely to be random with respect to the outcome, which can bias results toward the null. Yet, we were still able to observe significant associations. Second, our cancer analyses may have inadequate power to examine an association with more progressed types of baldness because of small number of CRC cases for frontal-plus-moderate-vertex baldness and frontal-plus-severe-vertex baldness. Yet, we attempted to address the limitation by complementing the cancer analyses with the adenoma analyses having approximately five times as many cases. Third, as male pattern baldness is a complex disorder determined by interplay of genetic and nongenetic factors, baldness pattern at different ages or rate of progressiveness may better capture the underlying factor responsible for an increased risk of colorectal neoplasia. However, our study with a single measurement of hair pattern could not address these questions. Finally, our findings may not be generalisable to other racial populations.

In conclusion, subtypes of male pattern baldness at age 45 years were positively associated with colorectal adenoma and cancer. To determine the predictive value of male pattern baldness in identifying those at high risk for colorectal neoplasia, our results need to be confirmed in future large epidemiologic studies. To better understand aetiologic mechanism linking male pattern baldness to colorectal neoplasia, additional studies are warranted to examine the association of sex hormones, IGFs, and insulin in relation to subtypes of male pattern baldness.
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###### Characteristics of person-years or endoscopy-years over 1992--2010 by male pattern baldness at age 45 years in HPFS

                                                           **Male pattern baldness**                                            
  ------------------------------------------------------- --------------------------- ------------- ------------- ------------- -------------
  **Colorectal cancer analysis**                                                                                                
  No. of person-years                                               224 070              131 004       86 103        40 528        28 802
  Age (year)                                                      66.7 (10.2)          66.9 (10.3)   66.1 (10.2)   67.4 (10.4)   66.8 (10.4)
  Caucasian (%)                                                      90.6                 91.7          91.4          90.8          92.7
  BMI (kg m^−2^)                                                  25.7 (3.2)           25.6 (3.1)    25.8 (3.2)    25.9 (3.5)    26.0 (3.3)
  Physical activity (MET-hours/week)                              33.8 (28.0)          33.4 (27.0)   32.8 (27.9)   33.1 (28.2)   32.8 (27.8)
  Personal history of diabetes mellitus (%)                           8.3                  8.1           8.4           8.4           9.5
  Personal history of endoscopy and polyp detection (%)              18.6                 18.6          18.9          18.1          19.4
  Family history of colon cancer (%)                                 16.2                 15.6          16.7          15.0          15.1
  Pack-years among ever smokers (pack-years)                      26.1 (20.4)          25.8 (20.3)   25.7 (20.8)   25.9 (20.1)   26.5 (19.7)
  Aspirin use[a](#t1-fn3){ref-type="fn"} (%)                         43.9                 44.5          44.5          44.8          45.9
  Multivitamin use (%)                                               52.7                 52.2          53.0          52.9          51.1
  Finasteride use (%)                                                 3.3                  3.5           3.8           4.1           3.9
  Alcohol (g day^−1^)                                             11.5 (13.6)          11.0 (13.0)   10.7 (13.2)   10.3 (12.5)   10.5 (13.5)
  Red/processed meat (servings per day)                            1.0 (0.7)            1.0(0.7)      1.0 (0.7)     1.0 (0.7)     1.0 (0.7)
  Folate[a](#t1-fn3){ref-type="fn"} (*μ*g day^−1^)                 493 (233)            489 (224)     490 (223      491 (230      483 (231)
  Calcium[a](#t1-fn3){ref-type="fn"} (mg day^−1^)                  907 (357)            906 (352)     898 (343)     900 (363)     892 (351)
  Vitamin D (IU day^−1^)                                           441 (238)            437 (229)     445 (234)     437 (232)     435 (239)
  **Colorectal adenoma analysis**                                                                                               
  No. of person-endoscopies                                         24 946               14 459         9993          4476          3283
  Age (year)                                                      65.8 (8.8)           66.0 (8.9)    65.4 (8.7)    66.3 (9.0)    65.7 (9.0)
  Caucasian (%)                                                      90.4                 91.5          91.6          89.2          92.0
  BMI (kg m^−2^)                                                  25.7 (3.1)           25.5 (3.0)    25.8 (3.1)    25.8 (3.2)    26.1 (3.4)
  Physical activity (MET-hours/week)                              35.0 (27.6)          35.7 (27.4)   34.3 (26.8)   34.9 (28.1)   33.6 (27.6)
  Personal history of diabetes mellitus (%)                           7.3                  7.5           7.1           7.4           8.7
  Family history of colon cancer (%)                                 18.1                 17.2          17.3          16.6          17.4
  Pack-years among ever smokers (pack-years)                      23.6 (19.0)          23.3(18.9)    22.5 (18.9)   23.3 (18.6)   25.3 (18.0)
  Aspirin use[a](#t1-fn3){ref-type="fn"} (%)                         44.7                 45.1          45.9          46.5          47.1
  Multivitamin use (%)                                               58.4                 57.9          58.9          58.4          58.1
  Finasteride use (%)                                                 3.3                  3.6           4.0           5.0           3.9
  Alcohol (g day^−1^)                                             11.3 (12.8)          10.9 (12.1)   10.9 (12.4)   10.4 (11.9)   10.5 (12.9)
  Red/processed meat (servings per day)                            1.0 (0.7)            1.0 (0.7)     0.9 (0.7)     0.9 (0.6)     0.9 (0.7)
  Folate[a](#t1-fn3){ref-type="fn"} (*μ*g day^−1^)                 497 (230)            493 (220)     496 (224)     499 (239)     501 (243)
  Calcium[a](#t1-fn3){ref-type="fn"} (mg day^−1^)                  905 (353)            906 (335)     906 (343)     893 (348)     902 (349)
  Vitamin D (IU day^−1^)                                           448 (233)            447 (221)     457 (231)     447 (233)     451 (234)

Abbreviations: BMI=body mass index; HPFS=Health Professionals Follow-Up Study; MET=metabolic equivalent task.

Values are mean (s.d.) or percentages and all, except age, are standardised to the age distribution of the study population during the follow-up.

Distribution of the variable at baseline was displayed in light of evidence suggesting a long induction period between the variable and colorectal neoplasia.

###### HR and 95% CI for male pattern baldness at age 45 years and total and site-specific colorectal cancer

                                               **Male pattern baldness**                                                                                  
  ------------------------------------------- --------------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Colorectal cancer**                                                                                                                                   
  No. of cases                                            285                     195                 133                 57                  40                  425
  Age adjusted[a](#t2-fn3){ref-type="fn"}            1 (Referent)          1.16 (0.96--1.39)   1.23 (1.00--1.52)   1.02 (0.76--1.36)   1.11 (0.79--1.55)   1.15 (0.99--1.34)
  Multivariable[b](#t2-fn4){ref-type="fn"}           1 (Referent)          1.13 (0.94--1.36)   1.22 (0.98--1.50)   0.99 (0.74--1.33)   1.09 (0.78--1.53)   1.13 (0.97--1.32)
  *P-*value for multivariable analysis                 Referent                  0.19                0.07                0.96                0.62                0.12
  **Colon cancer**                                                                                                                                        
  No. of cases                                            182                     140                 92                  37                  27                  296
  Age adjusted[a](#t2-fn3){ref-type="fn"}            1 (Referent)          1.32 (1.05--1.65)   1.33 (1.03--1.71)   1.02 (0.71--1.46)   1.16 (0.77--1.75)   1.26 (1.04--1.52)
  Multivariable[b](#t2-fn4){ref-type="fn"}           1 (Referent)          1.29 (1.03--1.62)   1.31 (1.01--1.70)   1.01 (0.70--1.45)   1.14 (0.75--1.72)   1.24 (1.02--1.50)
  *P-*value for multivariable analysis                 Referent                  0.02                0.04                0.96                0.55                0.03
  **Proximal colon cancer**                                                                                                                                         
   No. of cases                                           95                      76                  50                  21                  12                  159
   Age adjusted[a](#t2-fn3){ref-type="fn"}           1 (Referent)          1.37 (1.01--1.86)   1.43 (1.01--2.03)   1.09 (0.67--1.75)   0.97 (0.53--1.79)   1.31 (1.01--1.69)
   Multivariable[b](#t2-fn4){ref-type="fn"}          1 (Referent)          1.34 (0.99--1.83)   1.42 (1.00--2.02)   1.11 (0.68--1.80)   0.98 (0.53--1.81)   1.30 (1.00--1.68)
  * P-*value for multivariable analysis                Referent                  0.06                0.05                0.68                0.95                0.05
  **Distal colon cancer**                                                                                                                                           
   No. of cases                                           81                      60                  34                  16                  13                  123
   Age adjusted[a](#t2-fn3){ref-type="fn"}           1 (Referent)          1.28 (0.91--1.80)   1.06 (0.71--1.60)   1.01 (0.59--1.74)   1.31 (0.72--2.37)   1.17 (0.88--1.56)
   Multivariable[b](#t2-fn4){ref-type="fn"}          1 (Referent)          1.24 (0.88--1.75)   1.03 (0.68--1.56)   0.97 (0.56--1.68)   1.26 (0.69--2.32)   1.14 (0.85--1.51)
   *P-*value for multivariable analysis                Referent                  0.22                0.89                0.91                0.45                0.39
  **Rectal cancer**                                                                                                                                       
  No. of cases                                            64                      41                  24                  14                   9                  88
  Age adjusted[a](#t2-fn3){ref-type="fn"}            1 (Referent)          1.04 (0.70--1.55)   0.99 (0.61--1.61)   1.19 (0.66--2.14)   1.10 (0.54--2.22)   1.05 (0.76--1.46)
  Multivariable[b](#t2-fn4){ref-type="fn"}           1 (Referent)          1.05 (0.70--1.57)   1.04 (0.64--1.69)   1.24 (0.68--2.25)   1.05 (0.50--2.17)   1.08 (0.77--1.50)
  *P-*value for multivariable analysis                 Referent                  0.81                0.88                0.47                0.90                0.67

Abbreviations: CI=confidence interval; HR=hazard ratio.

Because of missing information on anatomic subsite for some colorectal cancer cases, the number of colon cancer and that of rectal cancer do not sum up to the number of colorectal cancer; the number of proximal colon cancer and that of distal colon cancer do not sum up to the number of colon cancer.

Stratified by age (years in continuous) and questionnaire cycle (integer indicating questionnaire cycle in continuous).

Additionally adjusted for race (White *vs* nonwhite), body mass index (BMI; kg m^−2^ in quintiles), physical activity (metabolic equivalent task (MET)-hours/week in quintiles), personal history of diabetes mellitus (yes *vs* no), personal history of endoscopy and polyp detection (no endoscopy+no polyp detection, endoscopy+no polyp detection, endoscopy+polyp detection), family history of colon cancer (yes *vs* no), smoking habits (never smoker, 0.1--4.9, 5--19.9, 20--39.9, 40+ pack-years), baseline aspirin use (yes *vs* no), current multivitamin use (yes *vs* no), total calorie intake (kcal day^−1^ in quintiles), alcohol intake (0, 0.1--4.9, 5.0--14.9, ⩾15 g day^−1^), red and processed meat intake (servings per day in quintiles), total folate intake at baseline (*μ*g day^−1^ in quintiles), total calcium intake at baseline (mg day^−1^ in quintiles), and total vitamin D intake (IU day^−1^ in quintiles).

###### OR and 95% CI for male pattern baldness at age 45 years and total and site-specific colorectal adenoma

                                               **Male pattern baldness**                                                                                  
  ------------------------------------------- --------------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Colorectum**                                                                                                                                          
  No. of cases                                           1490                     990                 571                 252                 223                2036
  Age adjusted[a](#t3-fn3){ref-type="fn"}            1 (Referent)          1.15 (1.05--1.25)   0.96 (0.87--1.06)   0.92 (0.80--1.06)   1.15 (0.99--1.33)   1.06 (0.99--1.13)
  Multivariable[b](#t3-fn4){ref-type="fn"}           1 (Referent)          1.16 (1.06--1.26)   0.96 (0.87--1.06)   0.93 (0.81--1.07)   1.14 (0.98--1.33)   1.06 (0.99--1.14)
  *P-*value for multivariable analysis                 Referent                 \<0.001              0.44                0.29                0.09                0.10
  **Colon**                                                                                                                                               
  No. of cases                                           1332                     877                 515                 219                 194                1805
  Age adjusted[a](#t3-fn3){ref-type="fn"}            1 (Referent)          1.13 (1.04--1.24)   0.97 (0.87--1.08)   0.90 (0.77--1.04)   1.11 (0.95--1.31)   1.05 (0.97--1.13)
  Multivariable[b](#t3-fn4){ref-type="fn"}           1 (Referent)          1.14 (1.04--1.25)   0.97 (0.87--1.08)   0.90 (0.77--1.04)   1.10 (0.94--1.30)   1.05 (0.97--1.13)
  *P-*value for multivariable analysis                 Referent                  0.004               0.57                0.16                0.23                0.20
  **Proximal colon**                                                                                                                                                
   No. of cases                                           856                     518                 315                 141                 138                1112
   Age adjusted[a](#t3-fn3){ref-type="fn"}           1 (Referent)          1.05 (0.94--1.18)   0.92 (0.80--1.05)   0.90 (0.74--1.08)   1.25 (1.03--1.51)   1.01 (0.92--1.11)
   Multivariable[b](#t3-fn4){ref-type="fn"}          1 (Referent)          1.06 (0.94--1.19)   0.91 (0.80--1.05)   0.90 (0.74--1.08)   1.23 (1.01--1.49)   1.01 (0.91--1.11)
   *P-*value for multivariable analysis                referent                  0.34                0.20                0.26                0.04                0.90
  **Distal colon**                                                                                                                                                  
   No. of cases                                           688                     501                 281                 113                 88                  983
   Age adjusted[a](#t3-fn3){ref-type="fn"}           1 (Referent)          1.27 (1.12--1.43)   1.02 (0.89--1.19)   0.89 (0.72--1.09)   0.98 (0.78--1.24)   1.11 (1.00--1.23)
   Multivariable[b](#t3-fn4){ref-type="fn"}          1 (Referent)          1.28 (1.13--1.44)   1.03 (0.89--1.19)   0.89 (0.73--1.10)   0.98 (0.77--1.24)   1.11 (1.01--1.24)
   *P-*value for multivariable analysis                Referent                 \<0.001              0.70                0.29                0.84                0.04
  **Rectum**                                                                                                                                              
  No. of cases                                            228                     158                 97                  48                  39                  342
  Age adjusted[a](#t3-fn3){ref-type="fn"}            1 (Referent)          1.21 (0.98--1.49)   1.07 (0.84--1.36)   1.15 (0.84--1.58)   1.32 (0.93--1.87)   1.17 (0.98--1.38)
  Multivariable[b](#t3-fn4){ref-type="fn"}           1 (Referent)          1.22 (0.99--1.51)   1.08 (0.85--1.38)   1.18 (0.86--1.63)   1.32 (0.93--1.87)   1.18 (0.99--1.40)
  *P-*value for multivariable analysis                 Referent                  0.06                0.53                0.30                0.12                0.06

Abbreviations: CI=confidence interval; OR=odds ratio.

When one is diagnosed with multiple adenomas in the colon, the individual was analysed based on the adenoma of the largest size and most advanced histologic characteristics except for analysis by anatomic location (proximal colon *vs* distal colon). Thus, the sum of proximal and distal adenomas exceed the number of colon adenomas.

Adjusted for age (\<64.9, 65--69.9, 70--74.9, 75--79.9, ⩾80 years), time period of endoscopy (integer indicating questionnaire cycle in continuous), number of endoscopies received (continuous), time since the most recent endoscopy (years in continuous), and reason for the current endoscopy (screening *vs* symptoms).

Additionally adjusted for race (White *vs* nonwhite), body mass index (BMI; kg m^−2^ in quintiles), physical activity (metabolic equivalent task (MET)-hours/week in quintiles), personal history of diabetes mellitus (yes *vs* no), family history of colon cancer (yes *vs* no), smoking habits (never smoker, 0.1--4.9, 5--19.9, 20--39.9, 40+ pack-years), baseline aspirin use (yes *vs* no), current multivitamin use (yes *vs* no), total calorie intake (kcal day^−1^ in quintiles), alcohol intake (0, 0.1--4.9, 5.0--14.9, ⩾15 g day^−1^), red and processed meat intake (servings per day in quintiles), total folate intake at baseline (*μ*g day^−1^ in quintiles), total calcium intake at baseline (mg day^−1^ in quintiles), and total vitamin D intake (IU day^−1^ in quintiles).

###### OR and 95% CI for male pattern baldness at age 45 years and colorectal adenoma by subtypes

                                                             **Male pattern baldness**                                                                                  
  --------------------------------------------------------- --------------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **By histopathology**                                                                                                                                                 
  **(Tubulo)villous**                                                                                                                                                             
   No. of cases                                                         300                     180                 106                 47                  38                  371
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.03 (0.86--1.25)   0.90 (0.72--1.12)   0.85 (0.62--1.16)   0.96 (0.68--1.35)   0.97 (0.83--1.13)
  **Tubular**                                                                                                                                                                     
   No. of cases                                                         908                     631                 347                 155                 148                1281
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.21 (1.09--1.34)   0.95 (0.84--1.08)   0.94 (0.79--1.12)   1.25 (1.04--1.50)   1.09 (1.00--1.20)
  **By size**                                                                                                                                                           
  **Large**                                                                                                                                                                       
   No. of cases                                                         448                     289                 150                 70                  56                  565
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.13 (0.96--1.32)   0.84 (0.70--1.02)   0.84 (0.65--1.09)   0.95 (0.71--1.27)   0.98 (0.86--1.12)
  **Small**                                                                                                                                                                       
   No. of cases                                                         903                     604                 366                 158                 147                1275
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.18 (1.05--1.31)   1.00 (0.88--1.14)   0.96 (0.80--1.15)   1.25 (1.04--1.52)   1.10 (1.00--1.20)
  **By multiplicity**                                                                                                                                                   
  **⩾3 Adenomas**                                                                                                                                                                 
   No. of cases                                                         216                     137                 89                  27                  25                  278
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.11 (0.89--1.38)   1.04 (0.81--1.34)   0.68 (0.46--1.02)   0.86 (0.57--1.31)   1.00 (0.83--1.20)
  **1--2 Adenomas**                                                                                                                                                               
   No. of cases                                                        1250                     839                 475                 221                 195                1730
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.17 (1.06--1.28)   0.95 (0.85--1.06)   0.97 (0.84--1.13)   1.19 (1.02--1.40)   1.07 (1.00--1.16)
  **By risk of progressing to CRC**                                                                                                                                     
  **High risk**                                                                                                                                                                   
   No. of cases                                                         639                     417                 225                 99                  82                  823
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.14 (1.00--1.29)   0.89 (0.76--1.04)   0.84 (0.68--1.05)   0.96 (0.76--1.22)   1.00 (0.90--1.11)
  **Low risk**                                                                                                                                                                    
   No. of cases                                                         587                     399                 224                 102                 102                 827
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.18 (1.04--1.35)   0.95 (0.81--1.11)   0.96 (0.78--1.20)   1.34 (1.08--1.66)   1.09 (0.98--1.22)
  **Large or ⩾3 adenomas by histology**                                                                                                                                 
  **Large or ⩾3 adenomas with (tubulo)villous histology**                                                                                                                         
   No. of cases                                                         221                     127                 86                  34                  28                  275
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.00 (0.80--1.25)   0.99 (0.77--1.28)   0.84 (0.58--1.21)   0.96 (0.64--1.44)   0.97 (0.81--1.16)
  **Large or ⩾3 adenomas with tubular histology**                                                                                                                                 
   No. of cases                                                         255                     188                 93                  38                  37                  356
   Multivariable[d](#t4-fn5){ref-type="fn"}                        1 (Referent)          1.28 (1.05--1.55)   0.92 (0.72--1.17)   0.81 (0.57--1.14)   1.10 (0.78--1.57)   1.08 (0.92--1.28)

Abbreviations: CRC=colorectal cancer; CI=confidence interval; OR=odds ratio.

*P-*value for multivariable analysis was 0.001 for tubular adenoma, 0.005 for small adenoma, 0.001 for 1--2 adenomas, 0.05 for high-risk adenoma, 0.01 for low-risk adenoma, and 0.01 for large or ⩾3 adenomas with tubular histology.

*P-*value for multivariable analysis was 0.02 for tubular adenoma, 0.02 for small adenoma, 0.03 for 1--2 adenomas, and 0.01 for low-risk adenoma.

*P-*value for multivariable analysis was 0.04 for tubular adenoma, 0.05 for small adenoma, and 0.07 for 1--2 adenomas.

Adjusted for the same set of variables as denoted in [Table 3](#tbl3){ref-type="table"}.

[^1]: These authors contributed equally to this work.
